OIS@ASRS 2017

Dugel Picks Possible Winners in Race to Deliver New Retinal Treatments

Dugel Picks Possible Winners in Race to Deliver New Retinal Treatments

By Mario Admin | September 19, 2017

Pravin Dugel, MD, managing partner, Retinal Consultants of Arizona,delivers a frank overview of the pipeline of experimental retinal drugs. The next year could be critical…

Read More
Blumenkranz Shares the Secrets and Insights That Won Him the OIS Innovator Award

Blumenkranz Shares the Secrets and Insights That Won Him the OIS Innovator Award

By Mario Admin | September 19, 2017

Mark S. Blumenkranz, MD, MMS, thanks many for the “humbling honor” of winning the OIS Lifetime Innovator Award. Dr. Blumenkranz, the chairman and managing director…

Read More
Grab a Peak at Allergan’s Ophthalmology Pipeline

Grab a Peek at Allergan’s Ophthalmology Pipeline

By Mario Admin | September 19, 2017

What retinal diseases are most interesting to Allergan? C. David Nicholson, PhD, chief R&D officer, discusses Allergan’s Phase III trials of Abicipar, a promising treatment…

Read More
ExSight’s Early Success Opening Door for New Fund?

ExSight’s Early Success Opening Door for New Fund?

By Mario Admin | September 19, 2017

Firas M. Rahhal, MD, a partner at ExSight Capital, had his hands full with his surgery practice in LA. But when a few high-profile patients…

Read More
Former Inspire CEO Shaffer Helps Start-Ups Find Out What Works

Former Inspire CEO Shaffer Helps Start-Ups Find Out What Works

By Mario Admin | September 18, 2017

Christy Shaffer, PhD, general partner at Hatteras Venture Partners, didn’t have a career map that led her into the corner office at Inspire Pharmaceuticals or…

Read More
B&L’s Roberts on How MDs Can Make Good CMOs

B&L’s Roberts on How MDs Can Make Good CMOs

By Mario Admin | September 18, 2017

In 2011, Cal Roberts, MD, got an unexpected call from Brent Saunders, then head of Bausch & Lomb. Saunders asked if Dr. Roberts would trade…

Read More
Drug-Delivery Panel Explores Emerging Platforms

Drug-Delivery Panel Explores Emerging Platforms

By Mario Admin | September 18, 2017

From injection of drug agents into the suprachoroidal space surrounding the eye to a port for injection of anti-VEGF therapy, a number of companies in…

Read More
Panel Analyzes Potential Obstacles to Combination Therapy

Panel Analyzes Potential Obstacles to Combination Therapy

By Mario Admin | September 18, 2017

Mark Humayun, MD, PhD, professor of ophthalmology at the University of Southern California, moderates a panel on combination drug delivery in age-related macular degeneration and…

Read More
Blumenkranz Identifies Inspiration for Innovative Life

Blumenkranz Identifies Inspiration for Innovative Life

By Mario Admin | September 18, 2017

Who inspires The Inspired? In an interview following his receiving the OIS Lifetime Innovator Award at OIS@ASRS in Boston, Mark S. Blumenkranz, MD, MMS, the…

Read More
Piper Jaffray Examines Public Market Trends in Ophthalmology

Public Market Trends in Ophthalmology

By Mario Admin | September 18, 2017

Andrew Gitkin, head of West Coast biotechnology investment banking at Piper Jaffray, examines first-half performance of critical markets. Also, what impact is Washington’s intransigence having…

Read More
What Could IPO and M&A Markets Look Like in the Coming Quarter?

What Could IPO and M&A Markets Look Like in the Coming Quarter?

By Mario Admin | September 6, 2017

What could the acquisition of TearScience and Kala Pharmaceuticals mean for the broader M&A and IPO activity? We ask Andrew Gitkin, managing director and head…

Read More

Cordeiro Explains How DARC May Help Detect Retinal Disease Earlier

By Mario Admin | August 28, 2017

Francesca Cordeiro, MD, PhD, professor, UCL and Imperial College London, Western Eye Hospital London, discusses a promising new technology that could enable much earlier detection…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.